These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 1778334)

  • 1. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups.
    Cherry JD; Mortimer EA; Hackell JG; Scott JV
    Dev Biol Stand; 1991; 73():51-8. PubMed ID: 1778334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group.
    Blumberg DA; Mink CM; Cherry JD; Johnson C; Garber R; Plotkin SA; Watson B; Ballanco GA; Daum RS; Sullivan B
    J Pediatr; 1991 Aug; 119(2):194-204. PubMed ID: 1907317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany.
    Heininger U; Cherry JD; Christenson PD; Eckhardt T; Göering U; Jakob P; Kasper W; Schweingel D; Laussucq S; Hackell JG
    Vaccine; 1994 Jan; 12(1):81-6. PubMed ID: 8303945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle's diphtheria and tetanus toxoids in two-, four- and six-month-old infants.
    Watson B; Cawein A; Mckee BL; Hackell JG
    Pediatr Infect Dis J; 1992 Nov; 11(11):930-5. PubMed ID: 1454434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K; Cherry JD
    Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
    Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
    Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
    Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
    Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of currently available Japanese acellular pertussis vaccines and future problems.
    Kamiya H; Nii R
    Tokai J Exp Clin Med; 1988; 13 Suppl():45-9. PubMed ID: 3273618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children.
    Glode M; Joffe L; Reisinger K; Blatter M; Plotkin S; Watson B; Grossman L; Asmar B; Berry M; Starobin S
    Pediatr Infect Dis J; 1992 Jul; 11(7):530-5. PubMed ID: 1528643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary report on household contact studies of the prevention of pertussis in Japanese children by Takeda diphtheria and tetanus toxoids and acellular pertussis vaccine combined.
    Mortimer EA
    Tokai J Exp Clin Med; 1988; 13 Suppl():29-34. PubMed ID: 3078807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.
    Morgan CM; Blumberg DA; Cherry JD; Reisinger KS; Blatter MM; Blumer JL; Dekker CL; Stout MG; Christenson PD
    Am J Dis Child; 1990 Jan; 144(1):41-5. PubMed ID: 2403747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Japanese clinical trials with Takeda acellular pertussis vaccine.
    Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
    Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.
    Blumberg DA; Mink CM; Cherry JD; Reisinger KS; Blatter MM; Congeni BL; Dekker CL; Stout MG; Mezzatesta JR; Scott JV
    J Pediatr; 1990 Jul; 117(1 Pt 1):46-51. PubMed ID: 2196360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers.
    Black SB; Shinefield HR; Bergen R; Hart C; Kremers R; Lavetter A; Lemesurier J; Morozumi PA; Ray P; Lewis EM; Fireman B; Schwalbe J; Hallam P; Shandling M; Dekker C; Granoff DM; Izu A; Podda A
    Pediatr Infect Dis J; 1997 Jan; 16(1):53-8. PubMed ID: 9002102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children.
    Kimura M; Kuno-Sakai H; Sato Y; Kamiya H; Nii R; Isomura S; Horiuchi K; Kato T; Deguchi M; Saikusa H
    Am J Dis Child; 1991 Jul; 145(7):734-41. PubMed ID: 2058603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.